News

News 06.12.2018 Zurich-Schlieren, Switzerland, and New York, December 6, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announces the continued progress of its pipeline of proprietary therapeutic product candidates in oncology and immuno-oncology, as well as in ophthalmology together...

News 06.12.2018 Schlieren (Zurich), Switzerland, December 6, 2018 – Kuros Biosciences (SIX: KURN) today announced the publication of data from a clinically-relevant preclinical model comparing MagnetOs with autologous bone in instrumented posterolateral spinal fusion in sheep. Utilizing multiple assessments for fusion, the study concluded that MagnetOs is a suitable alternative to autograft...

News 29.10.2018 Zurich-Schlieren, October 29, 2018. Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in...

News 24.10.2018 Schlieren (Zurich), Switzerland, October 22, 2018 – Kuros Biosciences AG (SIX: KURN) announced that its Dutch subsidiary, Kuros Biosciences BV, has recently been granted the US patent, US 10’064’892, entitled “Method for producing an osteoinductive calcium phosphate and products thus obtained” by the United States Patent and Trademark Office (USPTO). The patent covers...

News 05.09.2018 Financial highlights CHF 9.7 million cash at June 30 Operating expenses decreased to CHF 6.0 million Operational highlights First U.S. & European sales of MagnetOs Commercial rollout in the U.S. and Europe on track Preparation for Phase II clinical study of Fibrin-PTH in spine on track Download report